The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
accepted:
04
08
2022
pubmed:
30
8
2022
medline:
13
10
2022
entrez:
29
8
2022
Statut:
ppublish
Résumé
Multi-cancer early detection (MCED) testing could increase detection of cancer at early stages, when survival outcomes are better and treatment costs are lower, but is expected to increase screening costs. This study modeled an MCED test for 19 solid cancers in a US population and estimated the potential value-based price (the maximum price to meet a given willingness to pay) of the MCED test plus current single cancer screening (usual care) compared to usual care alone from a third-party payer perspective over a lifetime horizon. A hybrid cohort-level state-transition and decision-tree model was developed to estimate the clinical and economic outcomes of annual MCED testing between age 50 and 79 years. The impact on time and stage of diagnosis was computed using an interception modeling approach, with the consequences of cancer modeled based on stage at diagnosis. The model parameters were mainly sourced from the literature, including a published case-control study to inform MCED test performance. All costs were inflated to 2021 US dollars. Multi-cancer early detection testing shifted cancer diagnoses to earlier stages, with a 53% reduction in stage IV cancer diagnoses, resulting in longer overall survival compared with usual care. Addition of MCED decreased per cancer treatment costs by $5421 and resulted in a gain of 0.13 and 0.38 quality-adjusted life-years across all individuals in the screening program and those diagnosed with cancer, respectively. At a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained, the potential value-based price of an MCED test was estimated at $1196. The projected survival of individuals diagnosed with cancer and the number of cancers detected at an earlier stage by MCED had the greatest impact on outcomes. An MCED test with high specificity would potentially improve long-term health outcomes and reduce cancer treatment costs, resulting in a value-based price of $1196 at a $100,000/quality-adjusted life-year willingness-to-pay threshold.
Sections du résumé
BACKGROUND
Multi-cancer early detection (MCED) testing could increase detection of cancer at early stages, when survival outcomes are better and treatment costs are lower, but is expected to increase screening costs. This study modeled an MCED test for 19 solid cancers in a US population and estimated the potential value-based price (the maximum price to meet a given willingness to pay) of the MCED test plus current single cancer screening (usual care) compared to usual care alone from a third-party payer perspective over a lifetime horizon.
METHODS
A hybrid cohort-level state-transition and decision-tree model was developed to estimate the clinical and economic outcomes of annual MCED testing between age 50 and 79 years. The impact on time and stage of diagnosis was computed using an interception modeling approach, with the consequences of cancer modeled based on stage at diagnosis. The model parameters were mainly sourced from the literature, including a published case-control study to inform MCED test performance. All costs were inflated to 2021 US dollars.
RESULTS
Multi-cancer early detection testing shifted cancer diagnoses to earlier stages, with a 53% reduction in stage IV cancer diagnoses, resulting in longer overall survival compared with usual care. Addition of MCED decreased per cancer treatment costs by $5421 and resulted in a gain of 0.13 and 0.38 quality-adjusted life-years across all individuals in the screening program and those diagnosed with cancer, respectively. At a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained, the potential value-based price of an MCED test was estimated at $1196. The projected survival of individuals diagnosed with cancer and the number of cancers detected at an earlier stage by MCED had the greatest impact on outcomes.
CONCLUSIONS
An MCED test with high specificity would potentially improve long-term health outcomes and reduce cancer treatment costs, resulting in a value-based price of $1196 at a $100,000/quality-adjusted life-year willingness-to-pay threshold.
Identifiants
pubmed: 36038710
doi: 10.1007/s40273-022-01181-3
pii: 10.1007/s40273-022-01181-3
pmc: PMC9550746
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1107-1117Informations de copyright
© 2022. The Author(s).
Références
Curr Med Res Opin. 2022 Aug;38(8):1285-1294
pubmed: 35285354
Cancer. 2015 Aug 1;121(15):2637-45
pubmed: 25877511
NPJ Precis Oncol. 2018 Oct 29;2:23
pubmed: 30393772
JAMA Oncol. 2017 Sep 1;3(9):1278-1281
pubmed: 28152136
Ann Intern Med. 2021 Jan;174(1):25-32
pubmed: 33136426
Semin Oncol Nurs. 2017 May;33(2):121-128
pubmed: 28343835
Hum Genomics. 2019 Aug 1;13(1):34
pubmed: 31370908
Natl Vital Stat Rep. 2017 Aug;66(4):1-64
pubmed: 29155687
Med Decis Making. 2014 Aug;34(6):809-18
pubmed: 24903121
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
Ann Intern Med. 2019 Dec 3;171(11):796-804
pubmed: 31683314
Med Decis Making. 2007 May-Jun;27(3):288-98
pubmed: 17502448
J Gen Intern Med. 2006 Dec;21(12):1253-60
pubmed: 16961753
J BUON. 2016 Mar-Apr;21(2):320-5
pubmed: 27273940
Ann Oncol. 2020 Jun;31(6):745-759
pubmed: 33506766
Gynecol Oncol. 2009 May;113(2):216-20
pubmed: 19217148
Cancer. 2022 Feb 15;128 Suppl 4:892-908
pubmed: 35133662
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):460-468
pubmed: 33328254
Pharmacoeconomics. 2018 Oct;36(10):1273-1284
pubmed: 29948964
Anticancer Res. 2014 Feb;34(2):829-35
pubmed: 24511019
JAMA. 2018 May 8;319(18):1901-1913
pubmed: 29801017
Asian Pac J Cancer Prev. 2015;16(8):3345-50
pubmed: 25921142
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
Med Decis Making. 2010 Nov-Dec;30(6):685-93
pubmed: 20448248
Cancer. 2015 Mar 1;121(5):758-65
pubmed: 25369293
Science. 2020 Jul 3;369(6499):
pubmed: 32345712
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236